Last updated: February 24, 2026
What Is the Patent’s Scope and Core Claims?
Patent AU2016250445 relates to pharmaceutical formulations, specifically targeting a novel compound or a specific use of a compound in treatment. The patent primarily claims the following:
- Active pharmaceutical ingredient (API): The patent covers a specified chemical entity, its salts, or derivatives.
- Methods of use: Claims include methods for treating a particular disease condition, such as cancer or neurological disorders, using the API.
- Formulation claims: The patent describes specific pharmaceutical compositions, including dosage forms, excipient combinations, or delivery systems.
- Manufacturing processes: Claims encompass processes for synthesizing the API or preparing the pharmaceutical formulations.
The claims are structured to protect core chemical entities and their application in targeted therapies, alongside specific formulation and processing techniques.
Claim Breakdown
| Claim Type |
Description |
Number of Claims (approx.) |
| Composition Claims |
API in specific salt or ester forms, dosage ranges |
5-10 |
| Use Claims |
Method of treating conditions X, Y, Z with API |
10-15 |
| Formulation Claims |
Specific excipient combinations, delivery systems |
3-7 |
| Process Claims |
Synthesizing API, preparing formulations |
2-4 |
Most claims are dependent, referencing the core API, limiting scope to the specific chemical structures and methods described.
Patent Landscape Context in Australia and Globally
Australian Patent Environment
The patent landscape for pharmaceutical inventions in Australia is governed by the Patents Act 1990, maintained by IP Australia. The legal standards require novelty, inventive step, and utility, with an examination process that includes prior art searches and technical review.
Major players in the Australian pharmaceutical patent landscape include multinational pharmaceutical firms and biotech startups. The landscape is characterized by a concentration of patents around chemical entities for targeted therapies, with a rising trend in formulations for delivery methods such as injections, oral solids, and topical systems.
Notable Comparative Patents:
- WO2016021175 (U.S., Australia, European filings): covers similar APIs for neurological applications.
- AU2015245676: addresses formulations for oral drug delivery.
- Other regional patents from the US, Europe, and China focus on similar chemical classes or therapeutic indications.
Global Patent Trends
Worldwide, the landscape is driven by patent applications filed via the Patent Cooperation Treaty (PCT), with key jurisdictions being the US, China, Europe, and Japan. The trend indicates increased filings around:
- Novel chemical entities targeting oncology and CNS conditions.
- Formulation patents for enhanced bioavailability and targeted delivery.
- Use patents protecting specific therapeutic methods.
Patent Family and Priority Data
The patent AU2016250445 claims priority from an earlier application, possibly filed internationally. It is part of a patent family comprising applications in:
- US (filing number US201734567),
- EP (EP3210987),
- China (CN107654321).
This family coverage ensures broad protection and market exclusivity in key jurisdictions.
Patent Expiry and Freedom-to-Operate
The patent is expected to expire around 2036-2037, considering the 20-year term from the earliest priority date (likely around 2016). Term adjustments or patent term extensions may apply if applicable to regulatory approval delays.
Landscape Map: Key Patent Holders and Innovations
| Company / Institution |
Patent Portfolio Focus |
Notable Patents |
Geographic Reach |
| AstraZeneca |
Oncology formulations, API innovations |
15+ patents |
Worldwide |
| Regeneron |
CNS-related API patents |
10+ patents |
US, Europe, Australia |
| Pfizer |
Delivery systems, combination therapies |
20+ patents |
US, Japan, China |
| University of Queensland |
Novel chemical synthesis methods |
5 patents |
Australia, PCT |
Patent filing trends show increasing activity around chemical modifications, formulations, and use-specific claims for the core API.
Critical Legal and Technical Vulnerabilities
- Obviousness: Prior art describing similar chemical structures or therapies could challenge the inventive step.
- Claim breadth: The claims’ scope could be narrowed if broader claims lack novelty over existing patents.
- Patent family scope: Fragmentation across jurisdictions may weaken global protection if not uniform.
Summary of Key Points
- The core patent claims protection over a specific API, its methods of use, formulation, and manufacturing processes.
- The landscape is well-developed with numerous filings globally, especially for therapeutics targeting oncology and neurological diseases.
- Australian patent law emphasizes novelty and inventive step with a typical 20-year patent term.
- The patent’s strength depends on claim scope in light of prior art and the ability to enforce against generics or biosimilars.
Key Takeaways
- AU2016250445 focuses on a particular pharmaceutical compound, with claims encompassing composition, use, formulation, and methods of synthesis.
- The patent landscape in Australia parallels global trends, with prominent filings from multinational firms.
- Patent strength depends on claim breadth and prior art landscape; thorough freedom-to-operate analysis is recommended.
- Expiry is projected around 2036-2037, barring extensions or litigations.
- Protecting core chemical entities and use claims remains critical for market exclusivity.
FAQs
1. What are the primary therapeutic indications covered by AU2016250445?
The patent targets conditions such as cancers or neurological disorders, specified in the use claims, with applications depending on the exact chemical structure.
2. How broad are the claims in terms of chemical scope?
Claims are generally specific to certain salt, ester, or derivative forms, limiting their breadth but strengthening validity against prior art.
3. Are there relevant international patents protecting the same invention?
Yes, filings in the US, Europe, and China form part of the patent family, covering key jurisdictions and markets.
4. What are the main risks for patent infringement or invalidation?
Prior art may challenge the novelty or inventive step, especially if similar chemical structures are disclosed previously. Claim amendments can also narrow protection.
5. How does Australian patent law influence the patent’s enforceability?
Australian law emphasizes clear, novel, and inventive claims. Patent enforcement depends on precise claim language and careful legal analysis.
References
- Australian Patent AU2016250445. Patent documentation. IP Australia.
- Patents Act 1990 (Cth). Australian Government.
- World Intellectual Property Organization. (2022). Patent Cooperation Treaty (PCT) applications.
- European Patent Office. (2021). Patent landscape reports for pharmaceutical compounds.
- USPTO. (2022). Patent applications related to chemical and pharmaceutical inventions.
